A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...
The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.
New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
MILWAUKEE, WI, November 19, 2024 (EZ Newswire) -- As biopharmaceutical sponsors face increasing challenges in securing investigative sites for their clinical trials, the ability to reduce ...
The flowchart and steps below outlines the best practice for processing industry-written and sponsored clinical trials at UAB. There are many small steps in each of the larger defined steps (see flow ...
The integration of real-world data (RWD) into protocol feasibility and site selection has emerged as a clinical trial game-changer in recent years. Traditionally relying heavily on data from carefully ...
Healthcare providers receive data from many disparate sources: hospitals, doctors’ offices, labs and lab machines, medical devices, pharmacies, and more. Investment in the correct infrastructure to ...
In an era where precision medicine and rapid drug development are paramount, the clinical trials support software solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback